Nadofaragene Firadenovec in Non–Muscle-Invasive Bladder Cancer: Colin Dinney, MD

​High-grade non–muscle-invasive bladder cancer that does not respond to intravesical Bacillus Calmette-Guerin (BCG) therapy carries a substantial risk of disease recurrence and progression, and effective salvage intravesical therapies are sorely needed for patients who are unable or unwilling to undergo cystectomy. According to results of a multicenter, open-label phase 3 trial presented in February at the American Society of Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium, intrave...
Continue reading

RNF43 Variation and Cetuximab Efficacy in Metastatic Colorectal Cancer: Francesca Battaglin, MD

​In metastatic colorectal cancer, there has been a concerted effort to identify biomarkers that can predict the efficacy of existing treatments and support the development of new targeted therapies. As part of these efforts, Francesca Battaglin, MD, and colleagues investigated the association between cetuximab efficacy and gene expression levels and genetic variants in the R-Spondin/RNF43 complex. For their analysis, the researchers used genomic DNA from blood samples of participants in the phas...
Continue reading

Resecting Non–Contrast-Enhancing Tumor in Glioblastoma: Mitchel Berger, MD

​In patients with newly diagnosed glioblastoma, maximal extent of surgical resection of contrast-enhancing tumor has consistently been associated with benefits to survival. However, in a practice-changing study published recently in JAMA Oncology, a team of investigators under the leadership of Mitchel Berger, MD, found that extending resection to include non–contrast-enhancing tumor as well as contrast-enhancing tumor is associated with increased survival, regardless of tumor genetic subtype. I...
Continue reading

HSD3B1 Genotype and Prostate Cancer Outcomes: Nima Sharifi, MD

Men with metastatic castration-sensitive prostate cancer (CSPC) generally experience an initial response to androgen deprivation therapy (ADT), but with time, the cancer invariably becomes castration resistant. A new analysis of data from the phase 3 CHAARTED trial, published last week in JAMA Oncology, shows that men with low-volume metastatic CSPC who have the adrenal-permissive genotype of the HSD3B1 gene experience more rapid progression to castration-resistant disease and shorter overall su...
Continue reading

Baseline Liver Function As a Prognostic Factor in Unresectable HCC: Arndt Vogel, MD

In the phase 3 REFLECT trial, lenvatinib, an oral multikinase inhibitor, showed non-inferior survival compared with sorafenib in patients with untreated, unresectable hepatocellular carcinoma (HCC). However, the assessment of baseline liver function as a prognostic factor for patients with unresectable HCC receiving lenvatinib had not yet been investigated. In a post hoc analysis of the trial, a team of researchers led by Arndt Vogel, MD, Professor of Gastrointestinal Oncology at Hannover Medica...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.